New Weight-Loss drug candidate LAE103 enters early human safety trials
NCT ID NCT07230496
First seen Nov 17, 2025 · Last updated May 14, 2026 · Updated 23 times
Summary
This early-stage study tests the safety and tolerability of an experimental drug called LAE103 in healthy overweight or obese adults, and also in healthy postmenopausal women. Researchers will give single or multiple doses to see how the body processes the drug and if it causes side effects. A small group will also receive LAE103 together with another experimental drug, LAE102. The goal is to gather initial safety data, not to treat obesity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Q-Pharm Pty Ltd.
RECRUITINGBrisbane, Queensland, 4006, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.